Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LPTX Leap Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: LPTX
Price (delayed)
$0.3299
Market cap
$13.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.7
Enterprise value
-$19.84M
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator.
Highlights
LPTX's debt has dropped by 100% year-on-year
The EPS has increased by 20% year-on-year and by 6% since the previous quarter
The equity has dropped by 56% year-on-year and by 41% since the previous quarter
The quick ratio has dropped by 55% year-on-year and by 30% since the previous quarter
Key stats
What are the main financial stats of LPTX
Market
Valuations
Earnings
Shares outstanding
41.44M
Market cap
$13.67M
Enterprise value
-$19.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.65
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$71.15M
Net income
-$69.17M
EBIT
-$68.58M
EBITDA
-$68.57M
Free cash flow
-$59.26M
Per share
Balance sheet
Liquidity
EPS
-$1.7
EPS diluted
-$1.7
Free cash flow per share
-$1.44
Book value per share
$0.51
Revenue per share
$0
TBVPS
$0.85
Total assets
$34.88M
Total liabilities
$14.04M
Debt
$0
Equity
$20.84M
Working capital
$19.83M
Debt to equity
0
Current ratio
2.41
Quick ratio
2.44
Net debt/EBITDA
0.49
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-120.5%
Return on equity
-162.7%
Return on invested capital
N/A
Return on capital employed
-329.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LPTX stock price
How has the Leap Therapeutics stock price performed over time
Intraday
-7.12%
1 week
13.21%
1 month
-24.32%
1 year
-84.22%
YTD
-88.53%
QTD
11.11%
Financial performance
How have Leap Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.15M
Net income
-$69.17M
Gross margin
N/A
Net margin
N/A
Leap Therapeutics's net income has decreased by 30% YoY and by 2.4% from the previous quarter
The company's operating income fell by 20% YoY
Price vs fundamentals
How does LPTX's price correlate with its fundamentals
Growth
What is Leap Therapeutics's growth rate over time
Valuation
What is Leap Therapeutics stock price valuation
P/E
N/A
P/B
0.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 20% year-on-year and by 6% since the previous quarter
LPTX's P/B is 64% below its 5-year quarterly average of 1.8 and 62% below its last 4 quarters average of 1.7
The equity has dropped by 56% year-on-year and by 41% since the previous quarter
Efficiency
How efficient is Leap Therapeutics business performance
The return on equity has dropped by 101% year-on-year and by 18% since the previous quarter
The ROA has plunged by 75% YoY and by 13% from the previous quarter
Dividends
What is LPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LPTX.
Financial health
How did Leap Therapeutics financials performed over time
The company's total assets is 148% higher than its total liabilities
The current ratio has dropped by 55% year-on-year and by 29% since the previous quarter
The quick ratio has dropped by 55% year-on-year and by 30% since the previous quarter
LPTX's debt is 100% smaller than its equity
LPTX's debt has dropped by 100% year-on-year
The equity has dropped by 56% year-on-year and by 41% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.